Elena Paley
We reported the induction of neurotoxicity and neurodegeneration by tryptophan metabolites that link the metabolic alterations to Alzheimer’s disease (AD). Tryptophan is a product of Shikimate pathway (SP). Human cells lack SP, which is found in human gut bacteria using exclusively SP to produce aromatic amino acids (AAA). The presented study is a first attempt toward gene targeted analysis of human gut microbiota in AD fecal samples. The oligonucleotide primers newly designed for this work target of SP-AAA in environmental bacteria that is associated with the human activity. Using polymerase chain reaction (PCR) we found unique gut bacterial sequence in most AD patients (18 of 20) albeit rarely in controls (1 of 13). Cloning and sequencing AD-associated PCR products (ADPP) enable the identification of Na (+)-transporting NADHu. Biquinone reductase (NQR) in Clostridium sp. The ADPP of unrelated Alzheimer’s disease (AD) patients possess near identical sequences. NQR substrate ubiquinone is a SP product and also a human neuroprotectant. A deficit in ubiquinone has been determined in a number of neuromuscular and also in neurodegenerative disorders. The antibacterial therapy has prompted the ADPP reduction in ADPP-positive control person who has been later diagnosed with Alzheimer’s disease (AD)-dementia. We explored the gut microbiome databases and uncovered a sequence similarity up to 97% between ADPP and some healthy individuals from different geographical locations. The difference in gut microbial genotypes between Alzheimer’s disease (AD) and controls revealed in this study is the breakthrough finding. The test is suggested for a non-invasive laboratory monitoring of Alzheimer’s disease (AD) and related/associated disorders.